APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of
multi-source and branded injectable pharmaceutical products, today
reported financial results for the second quarter and six months
ended June 30, 2008. As a result of the separation of Abraxis
BioScience from APP Pharmaceuticals in the fourth quarter of 2007,
APP�s business is reported, for all periods presented, on a
continuing operations basis. Second Quarter 2008 Financial Results
Net revenues increased 24 percent to $197.9 million, compared with
$159.3 million in the second quarter of 2007. Gross profit
increased to $94.1 million, compared with $80.2 million in the
second quarter of 2007. Excluding $4.2 million for amortization of
purchased products, gross profit was $98.3 million, or 50 percent
of net revenues, compared with $84.3 million or 53 percent of net
revenues, in the second quarter of 2007. Total operating expenses
were $40.9 million, compared with $39.6 million in the 2007 second
quarter. Research and development expenses were $13.8 million
compared with $12.7 million in last year�s second quarter,
including costs associated with the technology transfer and
start-up of the Puerto Rico manufacturing facility. SG&A
expenses were $21.2 million, or 11 percent of net revenues,
compared with $22.7 million, or 14 percent of net revenues, in the
prior year second quarter. Income from operations increased 31
percent to $53.3 million compared with $40.6 million in the 2007
second quarter. Net interest expense was $13.5 million compared
with $4.4 million in the last year�s second quarter, primarily
reflecting the increase in borrowing following the separation of
Abraxis Bioscience, that was completed in November 2007. Net income
was $23.9 million, or $0.15 per diluted share, compared with second
quarter 2007 income from continuing operations, net of tax, of
$22.8 million or $0.14 per diluted share on a continuing operations
basis. The company reported adjusted income from continuing
operations of $38.5 million, or $0.24 per diluted share, compared
with $36.3 million, or $0.23 per diluted share, in the second
quarter of 2007, which in each case excludes Puerto Rico facility
pre-launch costs, amortization expense, non-cash stock compensation
expense, separation, merger and other non-recurring costs (see
table at the end of this release). �In the second quarter, solid
revenue growth across our product categories led to our strong
financial performance,� said Tom Silberg, APP Pharmaceuticals�
president and chief executive officer. �We have revised upward our
2008 financial guidance to reflect strong second quarter results as
well as positive trends in our Critical Care and
Anesthetic/Analgesic products.� First Six Months of 2008 Financial
Results Net revenues increased 15 percent to $346.0 million,
compared with $299.6 million for the first six months of 2007.
Gross profit was $164.2 million compared with $145.6 million, in
the first six months of 2007. Excluding $8.3 million for
amortization of purchased products, gross profit was $172.5
million, or 50 percent of net revenues, compared with $153.9
million or 51 percent of net revenues, in the first half of 2007.
Total operating expenses were $78.5 million, compared with $75.8
million in the comparable 2007 period. Research and development
expenses were $26.2 million compared with $22.6 million in first
six months of last year, including Puerto Rico technology transfer
costs. SG&A expenses were $42.2 million or 12 percent of net
revenues, compared with $44.7 million or 15 percent of net
revenues, in the prior year six month period. Income from
operations increased 23 percent to $85.7 million compared with
$69.8 million in the 2007 six month period. Net interest expense
was $29.3 million compared with $8.0 million in the first six
months of last year, primarily reflecting the increase in borrowing
following the Abraxis Bioscience separation. Net income, for the
six months ending June 30, 2008, was $33.0 million, or $0.20 per
diluted share, versus income from continuing operations, net of
tax, of $36.4 million, or $0.23 per diluted share. The company
reported adjusted net income from continuing operations of $60.5
million, or $0.38 per diluted share, compared with $62.6 million,
or $0.39 per diluted share, which in each case excludes Puerto Rico
facility pre-launch costs, amortization expense, non-cash stock
compensation expense, separation, merger and other non-recurring
costs (see table at the end of this release). APP currently has
approximately 65 product candidates in various stages of
development, including 25 ANDAs pending with the FDA, representing
approximately $4 billion in 2007 annualized branded sales. Recent
Events APP has received FDA final approval for Colistimethate for
Injection. Shortly after the end of the quarter, the Company
received final approvals and launched additional dosages of
Granisetron Hydrochloride Injection. 2008 Financial Guidance Total
net revenues are expected to be in the range of $800 to $820
million; Gross margin is anticipated to be approximately 51 to 52
percent relative to total net revenues. This excludes $16.4 million
in acquired product portfolio amortization and $2.1 million stock
compensation; R&D expense is expected to be approximately $25
to $30 million, excluding approximately $25 million associated with
technology transfer and capacity optimization of the Puerto Rico
manufacturing facility; SG&A expenses are anticipated to be in
the range of $75 to $80 million, which excludes expected non-cash
stock compensation expense of $6 million and approximately $20
million of merger and separation related expenses; Interest expense
is expected to be approximately $60 million; Income tax rate is
expected to be approximately 41 percent; Depreciation expense is
expected to be approximately $20 to $24 million; Adjusted EBITDA is
expected to be $325 to $350 million. Adjustments, as noted above,
reflect the exclusion of costs associated with the technical
transfer and operational start-up of the Puerto Rico facility,
expenses resulting from the separation of Abraxis Bioscience, costs
associated with the ongoing Fresenius merger activities, non-cash
compensation costs, and miscellaneous non-recurring costs; Adjusted
EPS, reported on a consistent basis as Adjusted EBITDA above, is
anticipated to be $0.85 to $0.95. Conference Call Information On
Friday, August 1, 2008, the company will host a conference call
with interested parties beginning at 7 a.m. PT (10 a.m. ET) to
review the company�s financial results. The conference call will be
available to interested parties through a live audio webcast at
www.APPpharma.com and www.thomsonone.com. The call will also be
archived and accessible at both sites for six months. Non-GAAP
Financial Measures The company believes that its presentation of
non-GAAP financial measures, such as adjusted net income, adjusted
income from continuing operations, EBITDA and adjusted EBITDA,
provides useful supplementary information to investors in
understanding the underlying operating performance of the company
and facilitates additional analysis by investors. The company also
uses non-GAAP financial measures internally for operating,
budgeting and financial planning purposes. The non-GAAP financial
measures are in addition to, and not a substitute for or superior
to, measures of financial performance calculated in accordance with
GAAP. A reconciliation of GAAP net income to adjusted net income
for the three and six months ending June 30, 2008 is included with
this news release. About APP Pharmaceuticals APP is a specialty
drug company that develops, manufactures and markets injectable
pharmaceutical products, focusing on oncology, anti-infective and
critical care markets. The company is one of the largest producers
of injectables, with more than 100 generic products in more than
400 dosage formulations. APP, headquartered in Schaumburg,
Illinois, has offices in Canada and manufacturing operations in
Illinois, New York and Puerto Rico and is traded on the Nasdaq
Global Market under the symbol APPX. For more information about APP
and the products it provides, please visit www.APPpharma.com.
Forward-Looking Statement The statements contained in this news
release that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in
this news release include statements regarding our expectations,
beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding financial guidance for 2008, trends
in our product lines, and the development and approval of product
candidates. Because these forward-looking statements involve risks
and uncertainties, there are important factors that could cause
actual results to differ materially from those in the forward-
looking statements. These factors include, but are not limited to,
the continued market acceptance and demand of new and existing
products; the difficulties or delays in developing, testing,
obtaining regulatory approval of, and producing and marketing of
the company�s products; the impact of competitive products and
pricing; the availability and pricing of ingredients used in the
manufacture of pharmaceutical products; and the ability to
successfully manufacture products in a time-sensitive and cost
effective manner. Additional relevant information concerning risks
can be found in APP Pharmaceuticals Form 10-K for the year ended
December 31, 2007 and other documents it has filed with the
Securities and Exchange Commission. The information contained in
this news release is as of the date of this release. APP assumes no
obligations to update any forward-looking statements contained in
this news release as the result of new information or future events
or developments. APP Pharmaceuticals, Inc. Consolidated Statements
of Operation (unaudited, in thousands, except per share amounts) �
� � � Three Months Ended June 30, Six Months Ended June 30, 2008
2007 2008 2007 Net revenues: Critical care $ 113,532 $ 89,579 $
204,714 $ 174,274 Anti-infective 59,296 50,749 102,256 90,529
Oncology 21,726 14,577 32,747 25,854 Contract manufacturing � 3,364
� � 4,422 � � 6,280 � � 8,938 � Total net revenues 197,918 159,327
345,997 299,595 Cost of sales � 103,771 � � 79,177 � � 181,788 � �
154,008 � Gross profit � 94,147 � � 80,150 � � 164,209 � � 145,587
� Percent to total net revenues 47.6 % 50.3 % 47.5 % 48.6 % �
Operating expenses Research and development 13,833 12,678 26,163
22,642 Selling, general and administrative 21,173 22,678 42,193
44,739 Amortization of merger related intangibles 3,857 3,856 7,713
7,712 Separation costs 1,212 352 1,603 704 Merger related costs �
805 � � - � � 805 � � - � Total operating expenses � 40,880 � �
39,564 � � 78,477 � � 75,797 � Percent to total net revenues 20.7 %
24.8 % 22.7 % 25.3 % Income from operations 53,267 40,586 85,732
69,790 Percent to total net revenues 26.9 % 25.5 % 24.8 % 23.3 %
Interest expense and other, net � (13,527 ) � (4,377 ) � (29,264 )
� (7,987 ) Income from continuing operations before income tax
39,740 36,209 56,468 61,803 Income tax expense � 15,848 � � 13,417
� � 23,419 � � 25,394 � Income from continuing operations, net of
income tax 23,892 22,792 33,049 36,409 Loss from discontinued
operations, net of tax � - � � 294 � � - � � (2,208 ) Net income $
23,892 � $ 23,086 � $ 33,049 � $ 34,201 � � Basic earnings (loss)
per share: Continuing operations $ 0.15 � $ 0.14 � $ 0.21 � $ 0.23
� Discontinued operations � - � � - � � - � � (0.02 ) Net income $
0.15 � $ 0.14 � $ 0.21 � $ 0.21 � � Diluted earnings (loss) per
share: Continuing operations $ 0.15 � $ 0.14 � $ 0.20 � $ 0.23 �
Discontinued operations � - � � - � � - � � (0.02 ) Net income $
0.15 � $ 0.14 � $ 0.20 � $ 0.21 � � Weighted - average common
shares outstanding: Basic � 160,375 � � 159,384 � � 160,443 � �
159,423 � Diluted � 161,155 � � 160,353 � � 161,287 � � 160,481 � �
Selected ratios as a percentage of total net revenues: Research and
development 7.0 % 8.0 % 7.6 % 7.6 % Selling, general and
administrative 10.7 % 14.2 % 12.2 % 14.9 % � � � APP
Pharmaceuticals, Inc. GAAP to Adjusted Earnings from Continuing
Operations Reconciliation (unaudited, in thousands, except per
share amounts) � � � Adjusted income from continuing operations and
adjusted income from continuing operations per diluted share are
defined as income from continuing operations and diluted earnings
from continuing operations per share, respectively, in each case
excluding the impact of, non-cash stock compensation expense,
separation related costs, amortization of acquired intangible
assets and merger related intangibles and Puerto Rico pre-launch
costs. We believe that our presentation of non-GAAP financial
measures provides useful supplementary information to investors in
understanding our underlying operating performance and facilitates
additional analysis by investors. We also use non-GAAP financial
measures internally for operating, budgeting and financial planning
purposes. The non-GAAP financial measures are in addition to, and
not a substitute for or superior to, measures of financial
performance calculated in accordance with GAAP. A reconciliation of
GAAP income from continuing operations to adjusted income from
continuing operations for the three months and six months ended
June 30, 2008 is below: For the three months ended June 30 � � For
the six months ended June 30 � 2008 � 2007 2008 � 2007 � Income
from continuing operations net of income tax $ 23,892 $ 22,792 $
33,049 $ 36,409 Stock compensation expense 925 2,129 2,787 4,619
Intangible amortization 2,784 2,616 5,523 5,234 Separation, merger
and other non-recurring costs 1,933 217 2,185 435 Amortization of
purchased product rights 2,538 2,538 5,076 5,076 Puerto Rico
pre-launch costs � 6,396 � 5,982 � 11,893 � 10,857 Adjusted income
from continuing operations $ 38,468 $ 36,275 $ 60,513 $ 62,630 �
Adjusted income from continuing operations per diluted share $ 0.24
$ 0.23 $ 0.38 $ 0.39 � Weighted - average common shares outstanding
diluted � 161,155 � 160,354 � 161,287 � 160,481 � Income from
continuing operations per diluted share $ 0.15 $ 0.14 $ 0.21 $ 0.23
Stock compensation expense 0.01 0.01 0.02 0.03 Intangible
amortization 0.02 0.02 0.03 0.03 Separation, merger and other
non-recurring costs 0.01 0.00 0.01 0.00 Amortization of purchased
product rights 0.01 0.02 0.03 0.03 Puerto Rico pre-launch costs �
0.04 � 0.04 � 0.08 � 0.07 Adjusted income from continuing
operations per diluted share $ 0.24 $ 0.23 $ 0.38 $ 0.39 � � � APP
Pharmaceuticals, Inc. Reconciliation of Income from Continuing
Operations to Adjusted EBITDA Three and Six Months Ended June 30,
2008 (unaudited, in thousands) � � � We define adjusted EBITDA from
continuing operations as income from continuing operations,
excluding the impact of depreciation and amortization, interest
expense net of interest income and other income, income tax
expense, non-cash stock-based compensation expense, separation
related costs and pre-launch costs associated with Puerto Rico
manufacturing facility. We use adjusted EBITDA from continuing
operations to provide meaningful supplemental information to
investors in understanding the underlying operating performance of
the business and facilitate additional analysis by investors. We
believe that adjusted EBITDA from continuing operations can assist
management and investors in assessing the financial operating
performance and underlying strength of our core business. Adjusted
EBITDA from continuing operations is not a recognized term under
GAAP and should not be considered in isolation of, or as a
substitute for, the information prepared and presented in
accordance with GAAP. Because not all companies calculate adjusted
EBITDA from continuing operations identically, our definition of
adjusted EBITDA from continuing operations may not be comparable to
similarly titled measures of other companies. � For the three
months ended June 30 � � For the six months ended June 30 2008 �
2007 2008 � 2007 � Income from continuing operations net of income
tax $ 23,892 $ 22,792 $ 33,049 $ 36,409 Depreciation 4,766 4,385
9,258 8,060 Amortization 8,009 8,347 16,004 16,696 Interest
expense, net of interest income 13,633 4,376 29,878 7,986 Provision
for income taxes from continuing operations � 15,848 � 13,417 �
23,419 � 25,394 EBITDA from continuing operations 66,148 53,317
111,608 94,545 � Stock-based compensation expense 1,498 3,448 4,513
7,480 Puerto Rico pre-launch costs, net of depreciation 6,409 6,104
11,356 11,079 Separation, merger and other non-recurring costs �
3,130 � 352 � 3,539 � 704 Adjusted EBITDA from continuing
operations $ 77,185 $ 63,221 $ 131,016 $ 113,808 � � � APP
Pharmaceuticals, Inc. Consolidated Condensed Balance Sheets (In
thousands) � � June 30, � � December 31, 2008 2007 Assets
(Unaudited) (Audited) Current assets: Cash and cash equivalents $
73,890 $ 31,788 Accounts receivable, net of allowances 73,387
85,209 Inventories 169,680 149,191 Prepaid expenses and other
current assets 13,792 13,531 Current receivables from related
parties - 6,996 Income tax receivable 1,471 - Deferred income taxes
� 16,020 � � 17,109 � Total current assets 348,240 303,824
Property, plant and equipment, net 131,476 132,528 Intangible
assets, net of accumulated amortization 447,949 463,154 Goodwill
160,239 160,239 Deferred financing costs and other non-current
assets, net � 17,159 � � 17,842 � Total assets $ 1,105,063 � $
1,077,587 � � Liabilities and stockholders' deficit Current
liabilities: Accounts payable $ 38,285 $ 36,502 Accrued liabilities
35,952 45,595 Current payable from related parties 1,024 - Fair
value of interest rate swap 2,084 - Short term portion of long term
debt � 11,250 � � 5,000 � Total current liabilities � 88,595 � �
87,097 � � Long-term debt 986,250 995,000 Deferred income taxes,
non-current 67,064 71,011 Other non-current liabilities � 4,841 � �
4,250 � Total liabilities 1,146,750 1,157,358 � Total stockholders'
deficit � (41,687 ) � (79,771 ) Total liabilities and stockholders'
deficit $ 1,105,063 � $ 1,077,587 �
App Pharmaceuticals (MM) (NASDAQ:APPX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
App Pharmaceuticals (MM) (NASDAQ:APPX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024